Jetema USA

Jetema is a South Korean biopharmaceutical company specializing in aesthetic and therapeutic medical products, with Jetema USA serving as its clinical and regulatory hub in the United States. The company's core portfolio includes botulinum toxin type A (JTM201) and a variety of hyaluronic acid-based dermal fillers marketed under the brand e.p.t.q. Jetema distinguishes itself through its high-purity toxin production technology and its focus on expanding into global markets, including the U.S. and Europe. The company is currently advancing clinical trials for its toxin products to address both cosmetic indications like glabellar lines and medical conditions such as spasticity. Jetema is one of the few companies in the industry to have secured a legitimate and documented strain of Clostridium botulinum, enhancing its regulatory standing. Through its US subsidiary, the company is actively pursuing FDA approval to compete in the lucrative North American aesthetics market.